Platycodin D2 is a potential less hemolytic saponin adjuvant eliciting Th1 and Th2 immune responses

International Immunopharmacology

Volumn 8, Issue 8, 2008, Pages 1143-1150

  Xie, Yong ^a,b   Deng, Wen ^a   Sun, Hongxiang ^a   Li, Duo ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Adjuvant; Cytokines; Haemolysis; Platycodin D2; Platycodon grandiflorum; Transcription factors

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CONCANAVALIN A; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MESSENGER RNA; OVALBUMIN; PLATYCODIN D2; PLATYCODON GRANDIFLORUM EXTRACT; QUIL A; SAPONIN DERIVATIVE; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ISOLATION; FEMALE; HEMOLYSIS; IMMUNOMODULATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TRANSCRIPTION REGULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; CELL PROLIFERATION; CYTOKINES; FEMALE; HEMOLYSIS; IMMUNITY, CELLULAR; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MICE; OVALBUMIN; SAPONINS; TH1 CELLS; TH2 CELLS; TRANSCRIPTION FACTORS; TRITERPENES;

EID: 50949087401     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.04.006     Document Type: Article

References (38)

1. O'Hagan D.T., Mackichan M.L., and Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 18 3 (2001) 69-85
2. Marciani D.J. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 8 (2003) 934-943
3. Rock K.L., Hearn A., Chen C.J., and Shi Y. Natural endogenous adjuvants. Springer Semin Immunopathol 26 3 (2005) 231-246
4. Storni T., Kündig T.M., Senti G., and Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev 57 (2005) 333-355
5. Livingston P.O., Adluri S., Helling F., Yao T.J., Kensil C.R., Newman M.J., et al. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12 (1994) 1275-1280
6. McKee A.S., Munks M.W., and Marrack P. How do adjuvants work? important considerations for new generation adjuvants. Immunity 27 (2007) 687-690
7. + T cell responses: the alternative approaches. Annu Rev Immunol 15 (1997) 297-322
8. Pascual D.M., Morales R.D., Gil E.D., Muñoz L.M., López J.E., and Casanueva O.L.J. Adjuvants: present regulatory challenges. Vaccine 24 S2 (2006) S88-S89
9. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20 Suppl. 3 (2002) S34-S39
10. Aguilar J.C., and Rodríguez E.G. Vaccine adjuvants revisited. Vaccine 25 (2007) 3752-3762
11. Azuma I., and Seya T. Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol 1 (2006) 1249-1259
12. Sparg S.G., Light M.E., and van Staden J. Biological activities and distribution of plant saponins. J Ethnopharmacol 94 (2004) 219-243
13. Lacaille-Dubois M.A. Bioactive saponins with cancer related and immunomodulatory activity: Recent developments. Stud Nat Prod Chem 32 12 (2005) 209-246
14. Skene C.D., and Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods 40 (2006) 53-59
15. Kensil C.R., and Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Exp Opin Invest Drugs 7 (1998) 1475-1482
16. + cytotoxic T cells by immunization with purified HIV-1 envelope proteins in ISCOMS. Nature 344 (1990) 873-875
17. Soltysik S., Wu J.Y., Recchia J., Wheeler D.A., Newman M.J., Coughlin R.T., et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 13 (1995) 1403-1410
18. Waite D.C., Jacobson E.W., Ennis F.A., Edelman R., White B., Kammer R., et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 19 (2001) 3957-3967
19. Keefer M.C., Wolff M., Gorse G.J., Graham B.S., Corey L., Clements-Mann M.L., et al. Safety profile of Phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS vaccine evaluation group. AIDS Res Hum Retrov 13 (1997) 1163-1177
20. Evans T.G., McElrath M.J., Matthews T., Montefiori D., Weinhold K., Wolff M., et al. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine 19 (2001) 2080-2091
21. + T-cell frequencies by the elispot assay in health individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer 87 (2000) 391-398
22. Chapman P.B., Morrissey D.M., Panageas K.S., Hamilton W.B., Zhan C., Destro A.N., et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS-21 vaccine: a dose-response study. Clin Cancer Res 6 (2000) 874-879
23. Ha Y.W., Na Y.C., Seo J.J., Kim S.N., Linhardt R.J., and Kim Y.S. Qualitative and quantitative determination of ten major saponins in Platycodi Radix by high performance liquid chromatography with evaporative light scattering detection and mass spectrometry. J Chromatogr A 1135 (2006) 27-35
24. Xie Y, Pan HJ, Sun HX, Li D. A promising balanced Th1 and Th2 directing immunological adjuvant, saponins from the root of Platycodon grandiflorum. Vaccine in press, doi:10.1016/j.vaccine.2008.01.061.
25. Ishii H., Tori K., Tozyo T., and Yoshimura Y. Saponins from roots of Platycodon grandiflorum. Part 2. isolation and structure of new triterpene glycosides. J Chem Soc Pekin Trans 1 10 (1984) 661-668
26. Santos W.R., Bernardo R.R., Pecanha L.M., Palatnik M., Parente J.P., and de-Sousa C.B. Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani. Vaccine 15 (1997) 1024-1029
27. Sun H.X., Ye Y.P., Pan H.J., and Pan Y.J. Adjuvant effect of Panax notoginseng saponins on the immune responses to ovalbumin in mice. Vaccine 22 (2004) 3882-3889
28. Limaa K.M., dos Santos S.A., Rodrigues Jr. J.M., and Silva C.L. Vaccine adjuvant: it makes the difference. Vaccine 22 (2004) 2374-2379
29. Oda K., Matsuda H., Murakami T., Katajama S., Oghitani T., and Yoshikawa M. Adjuvant and hemolytic activities of 47 saponins derived from medicinal and food plants. Biol Chem 381 (2000) 67-74
30. Nord L.I., and Kenne L. Separation and structural analysis of saponins in a bark extract from Quillja saponaria Molina. Carbohydr Res 320 (1999) 70-81
31. api. J Am Chem Soc 128 36 (2006) 11906-11915
32. Liu G., Anderson C., Scaltreto H., Barbon J., and Kensil C. QS-21 structure/function studies: effect of acylation on adjuvant activity. Vaccine 20 (2002) 2808-2815
33. Marciani D.J., Press J.B., Reynolds R.C., Pathak A.K., Pathak V., Gundy L.E., et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 18 (2000) 3141-3151
34. Finkelman F.D., Holmes J., Katona I.M., Urban Jr. J.F., Beckmann M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 8 (1990) 303-333
35. Germann T., Bongartz M., Dlugonska H., Hess H., Schmitt E., Kolbe L., et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 25 (1995) 823-829
36. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., and Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100 (2000) 655-669
37. Zheng W., and Flavell R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89 (1997) 587-596
38. Chakir H., Wang H., Lefebvre D.E., Webb J., and Scott F.W. T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3. J Immunol Methods 278 (2003) 157-169